| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.02 |